000520.KS(000520.KS)
000520.KS
Samil Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company specializing in the development and manufacturing of generic and specialty drugs, with a significant presence in the oncology and cardiovascular segments. The company operates primarily in South Korea and has been expanding its footprint in emerging markets across Asia.
Samil generates revenue primarily through the sale of generic pharmaceuticals, which benefit from lower production costs and established market demand. The company leverages its R&D capabilities to develop specialty drugs, allowing for higher pricing power and margins. Its competitive advantages include a robust distribution network and strategic partnerships with healthcare providers.
Regulatory approvals for new drug formulations
Market share changes in generic pharmaceuticals
Pricing pressures from competitors
Partnerships or collaborations with healthcare organizations
Regulatory changes impacting drug approval processes
Technological disruption in drug manufacturing and delivery
Intense competition from both local and international generic manufacturers
Potential for price wars in the generic drug market
High debt levels could strain liquidity, especially with negative cash flow
Potential pension obligations impacting financial stability
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but reduced consumer spending can impact sales of over-the-counter products.
Interest rates affect Samil's financing costs for R&D and capital expenditures, which are critical for growth. Higher rates could compress margins and reduce investment in new drug development.
moderate - The company's debt-to-equity ratio of 1.29 indicates reliance on debt financing, making it sensitive to credit conditions.
value - Investors may be attracted to the low price-to-sales ratio of 0.7x, indicating potential undervaluation.
high - The stock has shown significant volatility, with a 1-year return of -35.9%.